

BLMH Blocking Peptide (Center)

Synthetic peptide

Catalog # BP20513c

Specification**BLMH Blocking Peptide (Center) - Product Information**

Primary Accession [Q13867](#)
Other Accession [P70645](#), [P13019](#),
[Q8R016](#)

BLMH Blocking Peptide (Center) - Additional Information

Gene ID 642

Other NamesBleomycin hydrolase, BH, BLM hydrolase,
BMH, BLMH**Target/Specificity**The synthetic peptide sequence is selected
from aa 229-242 of Human BLMH**Format**Peptides are lyophilized in a solid powder
format. Peptides can be reconstituted in
solution using the appropriate buffer as
needed.**Storage**Maintain refrigerated at 2-8°C for up to 6
months. For long term storage store at
-20°C.**Precautions**This product is for research use only. Not
for use in diagnostic or therapeutic
procedures.**BLMH Blocking Peptide (Center) - Protein Information**

Name BLMH

FunctionThe normal physiological role of BLM
hydrolase is unknown, but it catalyzes the
inactivation of the antitumor drug BLM (a
glycopeptide) by hydrolyzing the**BLMH Blocking Peptide (Center) - Background**The normal physiological role of BLM
hydrolase is unknown, but it catalyzes the
inactivation of the antitumor drug BLM (a
glycopeptide) by hydrolyzing the carboxamide
bond of its B-aminoalaninamide moiety thus
protecting normal and malignant cells from
BLM toxicity (By similarity).**BLMH Blocking Peptide (Center) - References**

Barrow I.K.-P., et al. Submitted (AUG-1998) to
the EMBL/GenBank/DDBJ databases.
Ferrando A.A., et al. Cancer Res.
56:1746-1750(1996).
Broemme D., et al. Biochemistry
35:6706-6714(1996).
Kalnine N., et al. Submitted (OCT-2004) to the
EMBL/GenBank/DDBJ databases.
Ota T., et al. Nat. Genet. 36:40-45(2004).

carboxamide bond of its B-aminoalaninamide moiety thus protecting normal and malignant cells from BLM toxicity.

Cellular Location

Cytoplasm.

**BLMH Blocking Peptide (Center) -
Protocols**

Provided below are standard protocols that you may find useful for product applications.

- [Blocking Peptides](#)